GlassScriptPhysician profile
Chijioke Ukoha
NPI 1124066634
$1,986.10
in general payments reported to CMS, 2019-2025
26 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $287 · 2021: $468 · 2022: $216 · 2023: $425 · 2024: $346 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.03 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $356.16 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $129.68 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.22 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $87.72 | 2020-2023 | |
| Abbvie INC. | $76.16 | 2020-2023 | Vraylar |
| Pfizer INC. | $68.35 | 2019-2024 | |
| Glaxosmithkline, LLC. | $67.75 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $67.22 | 2022-2024 | Dexcom G6 Transmitter |
| Aprecia Pharmaceuticals, LLC | $63.96 | 2023 | Spritam |
| Lilly USA, LLC | $62.14 | 2020-2024 | Jardiance, Mounjaro |
| Avanir Pharmaceuticals, INC. | $60.71 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $60.14 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.23 | 2022-2025 | |
| Novo Nordisk INC | $39.21 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $30.97 | 2022 | |
| Merck Sharp & Dohme LLC | $28.08 | 2019-2021 | |
| Astellas Pharma US INC | $24.36 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $23.27 | 2023 | |
| Eisai INC. | $22.29 | 2021 | |
| Horizon Therapeutics Plc | $19.24 | 2022 | |
| Amarin Pharma, INC. | $18.47 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.55 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.78 | 2021 | |
| Dermira, INC. | $14.32 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.09 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chijioke Ukoha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.